Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases
The financing will power the global commercial launch of the company's Fluidity One system.
Fluidic Analytics has raised $31 million to continue developing its transformational products for characterising proteins and their behaviour. The proceeds of the financing will be used to continue the commercial roll-out of the company’s lab-tools pipeline and to develop further high-value clinical applications of its technology.
Proteins and their behaviour are crucial to understanding how diseases develop, identifying the way that drugs interact with their targets, and developing new methods for matching the right treatment to the right patient at the right time. DNA gives clues about what is likely to happen over a lifetime. Proteins and their behaviour tell us what is actually happening now. To date, the emergence of a deep understanding of the biology underlying disease and health in real time has been hampered by the shortcomings of existing tools for protein characterisation.
Fluidic Analytics’ products are based on a proprietary technology platform from the University of Cambridge. This platform was designed explicitly to give deep insights into the way that proteins fold, aggregate and interact by characterising them in solution – precisely as they exist in the body. These products have the potential to help researchers understand the mechanisms underlying conditions like Alzheimer’s disease, pharmaceutical companies develop more effective drugs, and patients gain access to more accurate diagnostics in the clinic, at the pharmacy or even at home.
“This financing will power the global commercial launch of our Fluidity One system and enable our team to bring our next two lab-tools products to market. It will also allow us to advance a number of high-potential clinical applications that could help us make an even bigger impact on the world. We are delighted to be working with investors who share our vision of helping people everywhere make better decisions about how diseases are diagnosed, treatments are developed, and personal well-being is maintained,” said Andrew Lynn, CEO, Fluidic Analytics.
“We are always looking for the brightest thinkers with the best teams and technology to back for the long-term, and we have found that in Fluidic Analytics. The progress that Fluidic has made to date has been exemplary. As we enter the century of biology, the world needs transformational technologies that can help us understand the full picture of how biology unfolds in daily life and we are delighted to be backing a company that is doing just that,” said Vishal Gulati, Healthtech VC, Draper Esprit.
Tim Rea, Investor, BGF, commented: “The team at Fluidic Analytics have built a potentially life-changing technology and brought their idea from concept to production in an incredibly short time. The market for pharmaceutical tools and technology is thriving and Fluidic Analytics has created products for which there is growing demand. We’re excited to be supporting the team as they scale up and take advantage of the significant opportunity to develop this critical technology further."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance